Combination Chemotherapy for Advanced Gastric Cancer
Author Information
Author(s): Oh S C, Park K H, Choi I K, Yoon S Y, Kim S J, Seo J H, Choi C W, Kim B S, Shin S W, Kim J S
Primary Institution: Korea University Medical Center
Hypothesis
The study aims to ascertain the efficacy and toxicity of docetaxel and cisplatin combined with oral UFT and leucovorin as a first-line treatment for patients with advanced gastric cancer.
Conclusion
The combination chemotherapy of docetaxel, cisplatin, oral UFT, and leucovorin is effective and tolerable for treating advanced gastric cancer.
Supporting Evidence
- The overall response rate was 50%, with 4 complete responses and 22 partial responses.
- Median survival duration was 48 weeks, with a median time to progression of 22 weeks.
- Neutropenia was the major toxicity, affecting 69.3% of patients.
Takeaway
Doctors tested a new combination of medicines to help people with advanced stomach cancer, and it worked well for many patients.
Methodology
52 patients received a combination of docetaxel, cisplatin, oral UFT, and leucovorin, with treatment cycles evaluated for efficacy and toxicity.
Potential Biases
Potential bias due to the non-randomized design and single-center study.
Limitations
The study had a small sample size and was limited to a single institution.
Participant Demographics
Median age was 56 years, with a range of 19–77 years; 37 males and 15 females.
Statistical Information
P-Value
0.0001
Confidence Interval
95% CI: 36.4–63.6%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website